诊断前血浆代谢组学与肌萎缩侧索硬化风险
该研究在5个前瞻性队列中采用巢状病例对照设计,纳入275例随访期间发生ALS的个体,用液相色谱-质谱检测404种已知血浆代谢物。31种代谢物与ALS风险相关(p<0.05),但多重比较校正后均不显著,代谢组学特征不能可靠区分病例与对照。
要点
- 诊断前血浆代谢组学特征不能可靠区分未来ALS病例与对照。
- 31/404种代谢物与ALS风险名义相关(p<0.05),但多重比较校正后不显著。
- ALS发病前数年可能存在广泛但不确定的代谢失调。
核心结论
- 诊断前数年采集的血浆代谢组学特征不能可靠区分症状前ALS病例与对照。
- 结果提示ALS发病前数年存在广泛但界定不清的代谢失调。
研究设计与样本
- 在5个前瞻性队列中采用巢状病例对照设计,纳入275例随访期间发生ALS的个体。
- 用液相色谱-质谱检测血浆代谢物,鉴定404种已知代谢物。
- 用条件logistic回归评估代谢物与ALS风险的关联,并用机器学习分析判断代谢组学特征能否区分病例与对照。
主要发现
- 404种代谢物中31种与ALS风险相关(p<0.05)。
- 观察到27种反向关联,涉及二酰甘油、三酰甘油、尿酸、嘌呤核苷及部分有机酸和衍生物。
- 观察到正向关联的包括1种胆固醇酯、2种磷脂酰胆碱和1种鞘磷脂。
- 限定于发病前5年内采血的病例时,显著关联增至67种(63种反向)。
- 多重比较校正后所有关联均不显著;偏最小二乘判别分析、弹性网回归、随机森林、支持向量机和加权相关网络分析均不能可靠区分病例与对照。
临床怎么用
- 目前不建议将诊断前血浆代谢组学用于ALS的早期筛查或风险预测。
- 代谢组学发现提示ALS前驱期存在代谢改变,但需进一步研究明确具体通路。
局限性
- 所有代谢物与ALS风险的关联在多重比较校正后均不显著。
- 代谢组学特征不能可靠区分未来ALS病例与对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To identify prediagnostic plasma metabolomic biomarkers associated with amyotrophic lateral sclerosis (ALS). METHODS: We conducted a global metabolomic study using a nested case-control study design within 5 prospective cohorts and identified 275 individuals who developed ALS during follow-up. We profiled plasma metabolites using liquid chromatography-mass spectrometry and identified 404 known metabolites. We used conditional logistic regression to evaluate the associations between metabolites and ALS risk. Further, we used machine learning analyses to determine whether the prediagnostic metabolomic profile could discriminate ALS cases from controls. RESULTS: A total of 31 out of 404 identified metabolites were associated with ALS risk (p < 0.05). We observed inverse associations (n = 27) with plasma levels of diacylglycerides and triacylglycerides, urate, purine nucleosides, and some organic acids and derivatives, while we found positive associations for a cholesteryl ester, 2 phosphatidylcholines, and a sphingomyelin. The number of significant associations increased to 67 (63 inverse) in analyses restricted to cases with blood samples collected within 5 years of onset. None of these associations remained significant after multiple comparison adjustment. Further, we were not able to reliably distinguish individuals who became cases from controls based on their metabolomic profile using partial least squares discriminant analysis, elastic net regression, random forest, support vector machine, or weighted correlation network analyses. CONCLUSIONS: Although the metabolomic profile in blood samples collected years before ALS diagnosis did not reliably separate presymptomatic ALS cases from controls, our results suggest that ALS is preceded by a broad, but poorly defined, metabolic dysregulation years before the disease onset.
引用
- Bjornevik K, Zhang Z, O'Reilly ÉJ, et al. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. 2019. PMID: 30926684. doi:10.1212/WNL.0000000000007401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。